Sunday, 11.9.2011
8.00-10.00 Main Hall (Aula Duza)
Oral presentations 1: Topic Highlights (OP1-OP6)
Chairs: Peter Laurberg (Aalborg, Denmark); Barbara Jarzab (Gliwice, Poland)
OP01 E7080 IN ADVANCED RADIOIODINE (RAI)-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC); RESULTS OF A MULTI-CENTER PHASE II TRIAL
Sherman SI1, Jarzab B2, Cabanillas ME1, Licitra L3, Pacini F4, Martins RG5, Robinson B6, Ball DW7, McCaffrey JC8, Shah MH9, Bodenner DL10, Allison R11, Newbold K12, Elisei R13, Gold A14, Andresen C14, O'Brien JP14, Schlumberger M15
1The University of Texas MD Anderson Cancer Center, Houston, United States, 2Centrum Onkologii Instytut of Gliwice, Gliwice, Poland, 3Istituto Nazionale dei Tumori, Milano, Italy, 4Azienda Ospedaliera Universitaria Senese, Siena, Italy, 5Seattle Cancer Care Alliance, Seattle, United States, 6Royal North Shore Hospital, St. Leonards, Australia, 7John Hopkins Medical Institutes, Baltimore, United States, 8H. Lee Moffit Cancer Center, Tampa, United States, 9Ohio State University School of Medicine, Columbus, United States, 10University of Arkansas, Little Rock, United States, 11The Royal Brisbane and Women's Hospital, Herston, Australia, 12Royal Marsden Hospital, Sutton, United Kingdom, 13Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, 14Eisai Inc., Woodcliff Lake, United States, 15Institut Gustave-Roussy, Villejuif, France
OP02 THE CLINICAL PI3K INHIBITOR GDC-0941 RADIO-SENSITISES THYROID CARCINOMA CELLS BY INHIBITING BOTH THE PI3K AND HIF-1 SIGNALLING PATHWAYS
Burrows N1, Williams J1, Babur M1, Resch J2, Williams K1, Brabant G2
1University of Manchester, Hypoxia and Therapeutics Group, School of Pharmacy, Manchester, United Kingdom, 2University of Lübeck, Clinical and Experimental Endocrinology, Lübeck, Germany
OP03 EFFECTS OF CHRONIC 3-IODOTHYRONAMINE ADMINISTRATION ON LIPID METABOLISM IN RODENTS
Chiellini G1, Assadi-Porter FM2, Haviland J2, Butz D2, Frascarelli S1, Pellegrini S3, Scanlan TS4, Zucchi R1
1University of Pisa, Dip. di Scienze dell'Uomo e dell'Ambiente, Pisa, Italy, 2University of Wisconsin, Madison, United States, 3University of Pisa, Dip. di Patologia Sperimentale, Pisa, Italy, 4Oregon Health & Science University, Portland, United States
OP04 NEUROENDOCRINE C CELLS OF THE MOUSE THYROID ORIGINATE FROM FOREGUT PROGENITORS IN THE ANTERIOR ENDODERM
Nilsson M1, Andersson L2, Westerlund J2, Carlsson T1, Parrillo L3, Zoppoli P3, Lania G4, Baldini A4, Fagman H1
1Cancer Center Sahlgrenska, Gothenburg University, Institute of Biomedicine, Göteborg, Sweden, 2Gothenburg University, Institute of Biomedicine, Göteborg, Sweden, 3IRGS, Biogem s.c.ar.l, Ariano Irpino, Italy, 4Telethon Institute of Genetics and Medicine, Naples, Italy
OP05 A MULTICENTER RANDOMIZED PROSPECTIVE TRIAL OF PERCUTANEOUS LASER ABLATION VERSUS FOLLOW-UP FOR THE TREATMENT OF COLD THYROID NODULES. SIX-MONTH RESULTS
Papini E1, Valcavi R2, Rago T3, Vitti P3, Gambelunghe G4, De Feo P4, Bizzarri G1, Pacella C2
1Regina Apostolorum Hospital, Department of Endocrinology, Albano Laziale, Italy, 2Thyroid Disease Center, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, 3Department of Endocrinology, University of Pisa, Pisa, Italy, 4Department of Internal Medicine and Endocrine and Metabolic Sciences, Perugia, Italy
OP06 A NOVEL CHIMERIC TSHR BIOASSAY DETECTS BOTH THYROID BLOCKING AND STIMULATING IMMUNOGLOBULINS
Olivo PD1, Kim J1, Larrimer A1, Klasen R1, Kanitz M2, Li Y1, Kahaly GJ2
1Diagnostic Hybrids, Inc. (A Quidel Company), Athens, United States, 2Gutenberg University Medical Center, Thyroid Research Laboratory, Mainz, Germany
10.00-10.10 Main Hall (Aula Duza)
Lissitzky Career Award
(The 2011 award is sponsored exclusively by Diagnostic Hybrids, Ohio, USA)
Chairs: Peter Laurberg (Aalborg, Denmark); Luigi Bartalena (Varese, Italy)
10.10-10.30
Coffee Break
10.30-12.00 Minor Hall
Symposium 1 Basic: Local control of thyroid hormone action
Chair: Agnieszka Piekielko-Witkowska (Warsaw, Poland); Marek Niedziela (Poznan, Poland)
Control of deiodinase expression in malignancy
Domenico Salvatore (Naples, Italy)
The essential role of D2 in bone
Duncan Bassett (London, UK)
Understanding the HPT axis in MCT8 deficiency
Heike Heuer (Jena, Germany)
10.30-12.00 Main Hall (Aula Duza)
Symposium 2 Clinical: Pregnancy and Graves’ disease
Chair: Jacques Orgiazzi (Lyon, France); Gerasimos Krassas (Thessaloniki, Greece)
Preconception counseling in Graves’ disease
John Lazarus (Cardiff, UK)
Side effects of antithyroid drugs
Bijay Vaidya (Exeter, UK)
Management of Graves’ hyperthyroidism in pregnancy
Luca Chiovato (Pavia, Italy)
12.00-13.00 Poster Exhibition Area
Lunch and Poster Discussions (see separate PDF for further information)
Thyroid Cancer (clinical) 1: Posters PO1-PO10 / Chair: Ulla Feldt-Rasmussen (Copenhagen, Denmark)
Thyroid Cancer (clinical) 2: Posters PO11-PO19 / Chair: Markus Luster (Ulm, Germany)
Thyroid Cancer (clinical) 3: Posters PO20-PO29 / Chair: Laura Fugazzola (Milan, Italy)
Thyroid Cancer (basic/translational) 1: Posters PO30-PO39 / Chair: Clara Alvarez (Santiago de Compostela, Spain)
Graves’ Orbitopathy 1: Posters PO40-PO53 / Chair: Valentin Fadeyev (Moscow, Russia)
Graves’ Hyperthyroidism 1: Posters PO54-PO65 / Chair: Paolo Vitti (Pisa, Italy)
Thyroid Hormone & Metabolism 1: Posters PO66-PO73 / Chair: Istvàn Szabolcs (Budapest, Hungary)
Hypothyroidism 1: Posters PO74-PO87 / Chair: Annick van den Bruel (Bruges, Belgium)
Cytology: Posters PO88-PO101 / Chair: Teresa Rago (Pisa, Italy)
Pregnancy: Posters PO102-PO115 / Chair: Milos Zarkovic (Belgrade, Serbia)
13.00-14.00 Main Hall (Aula Duza)
Lunch Symposium AstraZeneca
|
13:00-13:05 Welcome Barbara Jarzab (Poland) 13:05-13:10 Introduction Richard Kloos (USA) 13:10-13:50 Case studies Expert panel discussion with audience interaction RossellaElisei (Italy) and Lori Wirth (USA) 13:50-14:00 Summary and close Richard Kloos (USA) |
14.00-14.45 Main Hall (Aula Duza)
ETA Harington-de Visscher Prize Lecture
Francesca Carlomagno (Naples, Italy)
Thyroid cancer: role of RET and beyond
14.45-15.00
Coffee Break
15.00-15.45
Meet the Expert
MTE 1 (B) MTE Hall : Non-mammalian models to study thyroid development
Luca Persani (Milan, Italy)
MTE 2 (B) Senate Hall : Thyroid hormone resistance and metabolism
Krishna Chatterjee (Cambridge, UK)
MTE 3 (C) Lecture Hall: The role of thyroid hormone in heart failure
Warner Simonides (Amsterdam, The Netherlands)
MTE 4 (C) Minor Hall: Treatment of difficult cases of thyroid carcinoma
Martin Schlumberger (Paris, France)
16.00-18.00 Minor Hall
Oral presentations 2: Thyroid Cancer translational (OP7-OP14)
Chair: Furio Pacini (Siena, Italy); Malgorzata Karbownik-Lewinska (Lodz, Poland)
OP07 EPIDERMAL GROWTH FACTOR RECEPTOR-TARGETED NON-VIRAL DELIVERY OF THE SODIUM IODIDE SYMPORTER (NIS) GENE IN RADIOIODINE-REFRACTORY DIFFERENTIATED AND ANAPLASTIC THYROID CANCER
Dolp PA1, Klutz K1, Wunderlich N1, Grünwald GK1, Willhauck MJ1, Knoop K1, Vetter A2, Rödl W2, Wagner E2, Göke B1, Ogris M2, Spitzweg C1
1Ludwig-Maximilians-University, Department of Internal Medicine II, Munich, Germany, 2Ludwig-Maximilians-University, Department of Pharmacy, Center of Drug Research, Pharmaceutical Biotechnology, Munich, Germany
OP08 OUTCOME OF A CONSERVATIVE MANAGEMENT POLICY FOR FOLLICULAR THYROID CANCER - A PROSPECTIVE LONGITUDINAL COHORT STUDY
Mackay I1,2, Craig W1,2, Smart L2,3, Krukowski ZH1,2
1Aberdeen Royal Infirmary, Department of General Surgery, Aberdeen, United Kingdom, 2University of Aberdeen, Aberdeen, United Kingdom, 3Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
OP09 THE IODINE DEFICIENCY-INDUCED ANGIOGENIC PATHWAY IN THYROID CANCER CELLS OCCURS VIA A VEGF-HIF SIGNALLING PATHWAY THAT, IN CONTRAST WITH NON MALIGNANT CELLS, IS INDEPENDENT ON REACTIVE OXYGEN SPECIES
Gerard A-C1, Humblet K1, Derradji H2, Baatout S2, de ville de Goyet C1, Sonveaux P3, Denef J-F1, Colin IM1
1Universite catholique de Louvain, IREC, Pôle de Morphologie, Bruxelles, Belgium, 2Belgian Nuclear Centre, SCK-CEN, radiobiology unit, Mol, Belgium, 3Universite catholique de Louvain, IREC,Pôle de Pharmacologie Thérapeutique, Bruxelles, Belgium
OP10 FAMILIAL PAPILLARY THYROID CANCER PATIENTS DISPLAY AN ELEVATED CHROMOSOME FRAGILITY CHARACTERIZED BY TELOMERIC ASSOCIATION AND TELOMERE LOSS
Cantara S1, Pisu M1, Capuano S1, Capezzone M1, Frau D2, Caria P2, Marchisotta S1, Busonero G1, Formichi C1, Vanni R2, Pacini F1
1University of Siena, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, Siena, Italy, 2University of Cagliari, Department of Biomedical Technologies and Sciences, Monserrato, Italy
OP11 HUMAN LEUKOCYTE ANTIGEN-G POLYMORPHISM: A POTENTIAL MARKER OF HISTOLOGICAL AGGRESSIVENESS IN PAPILLARY THYROID CANCER
Dardano A1, Rizzo R2, Polini A1, Stignani M2, Tognini S1, Pasqualetti G1, Colato C3, Ferdeghini M3, Baricordi O2, Monzani F1
1University of Pisa, Department of Internal Medicine, Pisa, Italy, 2University of Ferrara, Department of Experimental and Diagnostic Medicine, Ferrara, Italy, 3University of Verona, Department of Morphological and Biomedical Sciences, Verona, Italy
OP12 HIGH-RESOLUTION-MELTING-CURVE ANALYSIS (HRM) FOR BRAFV600E AND NRAS MUTATION SCREENING IN ROUTINE AIR DRIED THYROID FNA SMEARS IS MORE RELIABLE AND MORE SENSITIVE THAN FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) PROBES ANALYSIS
Rehfeld C1, Krogdahl A2, Ferraz C1, Precht Jensen EM2, Bösenberg E1, Hegedüs L3, Paschke R1, Eszlinger M1
1University of Leipzig, Division of Endocrinology and Nephrology, Leipzig, Germany, 2Odense University Hospital, Department of Pathology, Odense, Denmark, 3Odense University Hospital, Department of Endocrinology and Metabolism, Odense, Denmark
OP13 MICRORNA EXPRESSION IN EXPERIMENTAL IN VITRO THYROID TUMORS MODELS
Floor S1, Pita JM1,2, Saiselet M1, Le Pennec S1, Libert F1, van Staveren WCG1, Maenhaut C1
1ULB, IRIBHM, Anderlecht, Belgium, 2de Patobiologia Molecular (CIPM), Português de Oncologia de Lisboa Francisco Gentil, Lisbone, Portugal
OP14 SERUM ANTI-THYROID ANTIBODIES (TAB): A POSSIBLE NEW POSITIVE PREDICTIVE PARAMETER IN HIGH AGGRESSIVE BREAST CANCER (BC)
Muller I1, Fiore E1, Belardi V1, Sabatini S1, Giustarini E1, Vitti P1, Giani C1
1University of Pisa, Endocrinology, Pisa, Italy
Oral presentations 3: Young Investigators Session (OP15-OP22)
Chair: Paul Banga (London, UK); Marek Ruchala (Poznan, Poland)
OP15 MIR-224 CONTRIBUTES TO TISSUE HYPOTHYROIDISM IN RENAL CANCER, TARGETING THE 3'UTR OF TYPE 1 5´-IODOTHYRONINE DEIODINASE
Boguslawska J1, Piekielko-Witkowska A1, Wojcicka A1, Master A1, Nauman A1
1The Medical Centre of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland
OP16 DEFICIENCY OF THE THYROID HORMONE TRANSPORTER MONOCARBOXYLATE TRANSPORTER 8 ALTERS THYROID MORPHOLOGY IN A PATIENT AND IN MICE
Wirth EK1, Sheu S-Y2, Chiu-Ugalde J1, Sapin R3, Klein MO4, Mossbrugger I5, Quintanilla-Martinez L5,6, Krude H7, Riebel T8, Rothe K9, Köhrle J1, Schmid KW2, Schweizer U1, Grüters A7
1Charité-Universitätsmedizin Berlin, Institut f. Experimentelle Endokrinolgie, Berlin, Germany, 2Universität Duisburg-Essen, Institut für Pathologie und Neuropathologie, Essen, Germany, 3Université de Strasbourg, Centre National de la Recherche Scientifique, Strasbourg, France, 4Centre Hospitalier et Universitaire de Nancy, Service D'Endocrinologie, Nancy, France, 5Helmholtz-Zentrum München, German Mouse Clinic, München, Germany, 6Eberhard Karls Universität Tübingen, Institut für Pathologie, Tübingen, Germany, 7Charité-Universitätsmedizin Berlin, Institut für Experimentelle Pädiatrische Endokrinologie, Berlin, Germany, 8Charité-Universitätsmedizin Berlin, Klinik für Strahlenheilkunde, Pädiatrische Radiologie, Berlin, Germany, 9Charité-Universitätsmedizin Berlin, Klinik für Kinderchirurgie, Berlin, Germany
OP17 SOMATIC HYPERMUTATION OF THE IMMUNOGLOBULIN HEAVY CHAIN VARIABLE-REGION OF THYROID STIMULATING ANTIBODIES DETERMINES BINDING TO THE TSH-RECEPTOR
Hargreaves C1, Dunn-Walters D2, Banga JP1
1King's College London School of Medicine, Diabetes and Endocrinology, London, United Kingdom, 2King’s College London School of Medicine, Immunobiology, London, United Kingdom
OP18 DETECTION OF PAX8/PPARG AND RET/PTC REARRANGEMENTS IN ROUTINE AIR DRIED FINE NEEDLE ASPIRATION (FNA) SMEARS
Ferraz C1, Krogdahl A2, Rehfeld C1, Precht Jensen EM2, Bösenberg E1, Hegedüs L3, Paschke R1, Eszlinger M1
1University of Leipzig, Division of Endocrinology and Nephrology, Leipzig, Germany, 2Odense University Hospital, Department of Pathology, Odense, Denmark, 3Odense University Hospital, Department of Endocrinology and Metabolism, Odense, Denmark
OP19 DUAL-OXIDASE 2 GENETIC MODIFICATIONS IN CHILDREN WITH HYPOTHYROIDISM: IDENTICATION AND FUNCTIONAL ANALYSIS OF VARIANTS AND MUTATIONS
Molinaro A1, De Marco G1, Montanelli L1, Agretti P1, Bagattini B1, Dimida A1, Ferrarini E1, Niccolai F1, Bottai S1, Ceccarelli C1, Brozzi F1, Pinchera A1, Vitti P1, Tonacchera M1
1Università di Pisa, Endocrinology and Metabolism, Pisa, Italy
OP20 RELATIONS BETWEEN MATERNAL FIRST-TRIMESTER AND NEWBORN THYROID HORMONE SERUM LEVELS: RESULTS FROM A LARGE POPULATION-BASED COHORT STUDY
Medici M1, de Rijke YB1,2, Peeters RP1, Visser W3, de Muinck Keizer-Schrama SMPF4, Hooijkaas H5, Tiemeier H6,7, Bongers-Schokking JJ4, Visser TJ1
1Erasmus Medical Center, Endocrinology, Rotterdam, Netherlands, 2Erasmus Medical Center - Sophia Children's Hospital, Clinical Chemistry, Rotterdam, Netherlands, 3Erasmus Medical Center - Sophia Children's Hospital, Obstetrics and Gynecology, Rotterdam, Netherlands, 4Erasmus Medical Center - Sophia Children's Hospital, Endocrinology, Rotterdam, Netherlands, 5Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 6Erasmus Medical Center, Epidemiology, Rotterdam, Netherlands, 7Erasmus Medical Center - Sophia Children's Hospital, Child and Adolescent Psychiatry, Rotterdam, Netherlands
OP21 IS COMPLETION THYROIDECTOMY FOLLOWING LOBECTOMY FOR LOW RISK THYROID CANCER MANDATORY?
Craig W1,2, Krukowski ZH1,2
1Aberdeen Royal Infirmary, Department of General Surgery, Aberdeen, United Kingdom, 2University of Aberdeen, Aberdeen, United Kingdom
OP22 SELECTIVE VENOUS CATHETERIZATION IN LOCALIZING OCCULT PERSISTENT MEDULLARY THYROID CARCINOMA
Hajje G1, Borget I2, Baudin E1, Hartl D3, Deschamps F4, Schlumberger M1, De Baere T4, Leboulleux S1
1Institut Gustave Roussy, Endocrinology-Oncology Department, Villejuif, France, 2Institut Gustave Roussy, Department of Statistics, Villejuif, France, 3Institut Gustave Roussy, Ear Nose Throat Department, Villejuif, France, 4Institut Gustave Roussy, Interventional Radiology Department, Villejuif, France
18.00-18.30 Main Hall (Aula Duza)
Special Report: The Fukushima Accident
Chair: Aldo Pinchera (Pisa, Italy); Leszek Krolicki (Warsaw, Poland)
Shigenobu Nagataki (Tokyo, Japan)
18.30-20.00 Main Hall (Aula Duza)
ETA 2011 Merck Serono Satellite Symposium
Subclinical hypothyroidism through all ages
Chairperson: George J. Kahaly (Mainz, Germany)
18.30 Welcome Introduction
George J. Kahaly (Mainz, Germany)
18.45 Management of subclinical hypothyroidism during pregnancy and the postpartum
Kris Poppe, (Brussels, Belgium)
19.10 Increased morbidity and cardiovascular risk in subclinical hypothyroidism
Simon H. Pearce (Newcastle upon Tyne, UK)
19.35 Personalized rationale for thyroid hormone replacement
Antonio C. Bianco (Miami, USA)
Symposium participants are cordially invited to a cocktail reception immediately following the event.
